2023-05-08 16:41:25 ET
- FibroGen press release ( NASDAQ: FGEN ): Q1 GAAP EPS of -$0.81 misses by $0.02 .
- Revenue of $36.16M (-40.6% Y/Y) beats by $4.64M .
- At March 31, 2023, cash – defined as cash, cash equivalents, investments, and accounts receivable – was $373.6 million, including proceeds received during the quarter from recent use of the Company’s at-the-market equity facility.
- We expect our cash, cash equivalents, investments, and accounts receivable to be sufficient to fund our operating plans through 2024.
For further details see:
FibroGen GAAP EPS of -$0.81 misses by $0.02, revenue of $36.16M beats by $4.64M